Validation of a Laboratory Test Measuring Natalizumab (Tysabri) Serum Levels in a Multiple Sclerosis Patient Cohort
Latest Information Update: 25 Apr 2019
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Acronyms IIT12
- 23 Apr 2019 Status changed from recruiting to completed.
- 05 Jul 2017 Planned End Date changed from 1 May 2017 to 1 May 2018.
- 05 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.